» Articles » PMID: 12586532

Improving CPAP Use by Patients with the Sleep Apnoea/hypopnoea Syndrome (SAHS)

Overview
Journal Sleep Med Rev
Date 2003 Feb 15
PMID 12586532
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

Though continuous positive airway pressure (CPAP) is the treatment of choice for the sleep apnoea/hypopnoea syndrome (SAHS), suboptimal adherence to CPAP is common. Internationally, some 5-50% of SAHS patients recommended for CPAP either reject this treatment option or discontinue within the first week, and 12-25% of remaining patients can be expected to have discontinued CPAP by 3 years. Biomedical investigations of patients' CPAP use reveal frequent adverse effects, weak prospective relationships between symptomatic or physiological disease severity and CPAP use, and moderate correlations between use and benefit. Relatively expensive high-technological interventions to improve CPAP use (e.g. "intelligent" CPAP, humidification) are the subject of several well-conducted studies favouring their effectiveness. More basic educational and behavioural supports, and low-technological interventions (e.g. chinstraps, mask re-fitting) appear valued, but are currently less rigorously evaluated. In other diseases with demanding treatment regimens, cognitive constructs including health attitudes and beliefs (health value, locus of control, chance, powerful others, self-efficacy) and mental and physical health status are significant predictors of adherence. The enhancement of multidisciplinary models with psychosocial interpretations may provide increased explanatory and interventional potential in models of CPAP use. While acknowledging the scarcity of evidence, a structured, multidisciplinary, cost-efficient model is suggested, containing educational, behavioural and technological components as basic support, and with high-expertise cognitive-behavioural intervention in more difficult cases of low CPAP use.

Citing Articles

Tracking continuous positive airway pressure adherence in obstructive sleep apnea patients before, during, and after the COVID-19 lockdown.

BaHammam A, Alhuqayl F, Alzaid I, Alzammam Z, Alhuqayl F, Rajeh B Ann Thorac Med. 2025; 20(1):56-61.

PMID: 39926402 PMC: 11804958. DOI: 10.4103/atm.atm_296_23.


A randomized, crossover trial of one night of oxygen therapy for obstructive sleep apnea in patients with fibrotic interstitial lung disease.

Han T, Xiang B, Liu Z, Guo X, Mao L, Liu X Sleep Breath. 2025; 29(1):75.

PMID: 39804535 DOI: 10.1007/s11325-025-03251-0.


Are noradrenergics combined with antimuscarinics the future pharmacologic treatment for obstructive sleep apnea? A systematic review and meta-analysis of randomized controlled trials.

Bady Z, Mohammed H, Aboeldahab H, Samir M, Aissani M, Mohamed-Hussein A Sleep Breath. 2024; 29(1):63.

PMID: 39715937 DOI: 10.1007/s11325-024-03227-6.


Compliance After Re-Prescription for Positive Airway Pressure in Obstructive Sleep Apnea Patients Who Failed Positive Airway Pressure Therapy.

Lee J, Jeong J, Lee J, Lee J, Choi J J Rhinol. 2024; 29(3):148-154.

PMID: 39664301 PMC: 11524368. DOI: 10.18787/jr.2022.00417.


Obstructive sleep apnea in patients with fibrotic interstitial lung disease (non-idiopathic pulmonary fibrosis): what should be offered?.

Cardoso C, Valente C, Serino M, Rodrigues I, Carvalho A, Coelho D J Bras Pneumol. 2024; 50(5):e20240058.

PMID: 39661832 PMC: 11601067. DOI: 10.36416/1806-3756/e20240058.